By: PRLog
DCA and Radiation Effect Complete Long Term Remission of Previously 'Incurable' Cancer
PR Log - Nov 07, 2012 - Dicholoracetate (DCA) received much media attention in 2007 when Evangelos Michelakis of the University of Alberta reported that it dramatically shrank tumours across a broad spectrum of cancers in mice.  The media stir had patients clamouring for the drug before it passed the traditional trials.  Michelakis’ warning (amongst others) against taking the drug before the trials fell on deaf ears with a spate of online sites springing up selling the cheap, relatively simple, and generally well tolerated substance.

There was a big problem with DCA which had nothing to do with its pharmacology;  It wasn’t patentable.  To bring a drug to market, it costs a pharmaceutical company in the neighbourhood of a billion dollars which means that a watertight patent is required to ensure that the company receives return on investment.  As such, the drug was largely ignored by the mainstream pharmaceutical market.

To read the full release, please visit:

Read Full Story - DCA and Radiation Effect Complete Long Term Remission of Previously 'Incurable' Cancer | More news from this source

Press release distribution by PRLog

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here